» Articles » PMID: 28543940

Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass

Overview
Date 2017 May 26
PMID 28543940
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Romosozumab is a monoclonal antibody that inhibits sclerostin and has been shown to reduce the risk of fractures within 12 months. In a phase II, randomized, placebo-controlled clinical trial of treatment-naïve postmenopausal women with low bone mass, romosozumab increased bone mineral density (BMD) at the hip and spine by the dual effect of increasing bone formation and decreasing bone resorption. In a substudy of that trial, which included placebo and teriparatide arms, here we investigated whether those observed increases in BMD also resulted in improvements in estimated strength, as assessed by finite element analysis. Participants received blinded romosozumab s.c. (210 mg monthly) or placebo, or open-label teriparatide (20 μg daily) for 12 months. CT scans, obtained at the lumbar spine (n = 82) and proximal femur (n = 46) at baseline and month 12, were analyzed with finite element software (VirtuOst, O.N. Diagnostics) to estimate strength for a simulated compression overload for the spine (L vertebral body) and a sideways fall for the proximal femur, all blinded to treatment assignment. We found that, at month 12, vertebral strength increased more for romosozumab compared with both teriparatide (27.3% versus 18.5%; p = 0.005) and placebo (27.3% versus -3.9%; p < 0.0001); changes in femoral strength for romosozumab showed similar but smaller changes, increasing more with romosozumab versus teriparatide (3.6% versus -0.7%; p = 0.027), and trending higher versus placebo (3.6% versus -0.1%; p = 0.059). Compartmental analysis revealed that the bone-strengthening effects for romosozumab were associated with positive contributions from both the cortical and trabecular bone compartments at both the lumbar spine and hip. Taken together, these findings suggest that romosozumab may offer patients with osteoporosis a new bone-forming therapeutic option that increases both vertebral and femoral strength within 12 months. © 2017 American Society for Bone and Mineral Research.

Citing Articles

Romosozumab for the treatment of osteoporosis - a systematic review.

Makinen V, Solling A, McClung M, Langdahl B J Endocrinol Invest. 2024; 48(3):547-572.

PMID: 39487940 DOI: 10.1007/s40618-024-02469-1.


[Osteoporosis-Definition, risk assessment, diagnosis, prevention and treatment (update 2024) : Guidelines of the Austrian Society for Bone and Mineral Research].

Dimai H, Muschitz C, Amrein K, Bauer R, Cejka D, Gasser R Wien Klin Wochenschr. 2024; 136(Suppl 16):599-668.

PMID: 39356323 PMC: 11447007. DOI: 10.1007/s00508-024-02441-2.


Teriparatide in postmenopausal osteoporosis: uncovering novel insights into efficacy and safety compared to other treatments - a systematic review and meta-analysis.

Vithran D, Essien A, Rahmati M, Opoku M, Yon D, Lopez Sanchez G EFORT Open Rev. 2024; 9(9):845-861.

PMID: 39222329 PMC: 11457814. DOI: 10.1530/EOR-23-0205.


Treatment effects, adverse outcomes and cardiovascular safety of romosozumab - Existing worldwide data: A systematic review and meta-analysis.

Wong R, Wong P, Liu C, Wong H, Fong M, Zhang N J Orthop Translat. 2024; 48:107-122.

PMID: 39189010 PMC: 11345130. DOI: 10.1016/j.jot.2024.07.011.


Monthly treatment with romosozumab for 1 year increases bone mineral at the hip, but not the knee, in women with chronic spinal cord injury.

Crack L, Simonian N, Schnitzer T, Edwards W JBMR Plus. 2024; 8(7):ziae077.

PMID: 38911320 PMC: 11193877. DOI: 10.1093/jbmrpl/ziae077.